Sensus Healthcare, Inc.
NASDAQ:SRTSMedical - Devices
+$0.09 today
- Market cap
- $53.01M
- Beta
- 1.09
- P/E (TTM)
- -6.5
- EPS (TTM)
- -$0.47
Volume 0.08M
Average 0.06M
SRTS Accounts Receivables
Cash effect of the change in amounts owed by customers; growing receivables consume cash.
Sensus Healthcare, Inc.NASDAQ: SRTS
Accounts Receivables · Q1 FY2026 · quarter ended Mar 2026
Accounts receivables grows, but more slowly than its trailing trend
Q1 FY2026 accounts receivables of $2.46M rose 43.8% year over year, behind the +870.1% change in trailing-twelve-month accounts receivables. Sequentially, it fell 25.3% from the prior quarter.
Context
- Accounts receivables amounted to 49.7% of revenue in FY2025, up 27.6 pp from a year earlier.
- Accounts receivables increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +43.8% toward the trailing-twelve-month pace of +870.1%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Accounts Receivables history
USD · from the cash flow
- Latest · FY2025
- 13.65M USD
- Year-over-year change
- +248.2%
| Period | Period end | Accounts Receivables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 13.65M | +248.2% |
| FY2024 | 2024-12-31 | (9.21M) | -238.5% |
| FY2023 | 2023-12-31 | 6.65M | +225.1% |
| FY2022 | 2022-12-31 | (5.31M) | +37.0% |
| FY2021 | 2021-12-31 | (8.43M) | — |
Accounts Receivables vs competitors
How SRTS compares with its peers on the latest reported figures
- SRTS's LTM Mar 2026 accounts receivables of $14.4M is the largest of the 6 companies compared; the peer median is $1.51M.
- Its year-over-year change of +870.1% is the highest of 5, against a peer median of +281.3%.
- Accounts receivables amounts to 63.9% of revenue for SRTS, versus a peer median of 6.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $14.4M | +870.1% | — | 63.9% | |
| LTM Mar 2026 | $11.89M | +385.7% | — | 7.9% | |
BDMDBaird Medical Investment Holdings Limited | FY2025 | $5.35M | +130.0% | — | 23.7% |
| LTM Jun 2026 | $1.51M | +176.9% | -64.3% | 1.9% | |
MDAISpectral AI, Inc. | LTM Mar 2026 | $918K | +433.8% | — | 5.5% |
| LTM Mar 2026 | $0 | — | — | — | |
| Peer median (excluding SRTS) | $1.51M | +281.3% | -64.3% | 6.7% | |
Competitors are the stored peer set for SRTS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 4.12M | 24.24M | 485K | 6.65M | (7.72M) |
| Depreciation & Amortization | 613K | 509K | 461K | 432K | 626K |
| Deferred Income Tax | 0 | (1.71M) | (427K) | (57K) | (1.88M) |
| Stock-Based Compensation | 415K | 187K | 328K | 323K | 295K |
| Change in Working Capital | (6.14M) | (12.92M) | (3.56M) | (8.55M) | 8.66M |
| Accounts Receivables | (8.43M) | (5.31M) | 6.65M | (9.21M) | 13.65M |
| Inventory | 2.74M | (3.19M) | (8.58M) | 268K | (4.64M) |
| Accounts Payables | 962K | 799K | (2.73M) | 2.02M | (1.47M) |
| Other Working Capital | (1.4M) | (5.22M) | 1.1M | (1.63M) | 1.12M |
| Other Non-Cash Items | 705K | (11.72M) | 568K | 378K | 547K |
| Operating Cash Flow | (286K) | (1.41M) | (2.15M) | (831K) | 528K |
| Capital Expenditures | (128K) | (159K) | (229K) | (276K) | (196K) |
| Acquisitions (Net) | 257K | 15M | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 42K | 0 | 0 |
| Investing Cash Flow | 129K | 14.84M | (187K) | (276K) | (196K) |
| Debt Repayment | (216K) | (51K) | 0 | 0 | 0 |
| Common Stock Issued | 0 | 0 | 0 | 67K | 0 |
| Common Stock Repurchased | (15K) | (3M) | (27K) | 0 | (300K) |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | 622K | (13K) | (52K) | (5K) |
| Financing Cash Flow | (231K) | (2.43M) | (40K) | 15K | (305K) |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (388K) | 11M | (2.37M) | (1.09M) | 27K |
| Free Cash Flow | (414K) | (1.57M) | (2.37M) | (1.11M) | 332K |
Sensus Healthcare, Inc.
NASDAQ:SRTS
Intrinsic Alpha fair value
Locked
Current Price
$3.22
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.